LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial

Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susanne Krege, Jürgen Gschwend, Heidrun Rexer, Kerstin Junker, Roger Zillmann, Christoph Rüssel, Eva Hellmis, Henrik Suttmann, Martin Janssen, Jan Marin, Michael Stöckle, Andreas Hübner, Michael Mathers, Jochen Gleißner, Michael Scheffler, Susan Feyerabend, Jens Telle, Jörg Klier and Michael Stöckle

© The Author(s) 2023, corrected publication 2023

INTRODUCTION
Prostate cancer (PC) is the second most common cancer diagnosed in men and the fifth leading cause of death worldwide [1]. PC is typically castration-sensitive at the time of initial diagnosis, but the majority of patients undergoing androgen deprivation therapy (ADT) develop castration-resistant PC (CRPC) [2]. Changes in the normal androgen receptor signaling pathway are considered crucial for CRPC pathogenesis [3].

Abiraterone acetate (AA) is a prodrug of abiraterone, which is a selective and irreversible inhibitor of 17α-hydroxylase/C17,20-lyase (cytochrome P450C17[CYP17]), a key enzyme in testosterone synthesis [4]. AA plus prednisone (P) is approved in Europe in combination with LHRH therapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) upon pre-treatment with docetaxel, based on the results of the COU-AA-301 study [5] and for the treatment of chemotherapy-naïve asymptomatic or mildly symptomatic mCRPC patients based on the results of the COU-AA 302 study [6].

Treatment of mCRPC patients with AA + P leads to an increase in median survival compared to P alone [7, 8]. Results from the COU-AA-302 study revealed that progression-free survival (PFS) was significantly improved by treatment with AA + P [9] and overall survival (OS) was prolonged compared with P [6]. In castrated patients receiving LHRH-therapy and treated with AA + P testosterone further decreased to undetectable levels [10] suggesting that AA + P may induce and maintain testosterone deprivation without concomitant LHRH therapy.

Although AA + P may maintain androgen deprivation in the absence of LHRH-therapy, treatment without concomitant LHRH-therapy may impair efficacy of AA + P due to androgen suppression (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary.

METHODS: In this exploratory phase 2 study, mCRPC patients were randomized with a 1:1 ratio to receive either continued ADT plus AA + P (Arm A) or AA + P alone (Arm B). The primary endpoint was the rate of radiographic progression-free survival (rPFS) at month 12. Secondary endpoints included PSA-response rate, objective response, time to PSA progression and safety.

RESULTS: A total of 68 patients were equally randomized between the two study arms. Median testosterone-levels remained below castrate-levels throughout treatment in all patients. According to the intention-to-treat analysis the rPFS rate was 0.84 in Arm A and 0.89 in Arm B. Moderate and severe treatment-emergent adverse events were reported for 72% of the patients in Arm A and for 85% of the patients in Arm B.

CONCLUSIONS: AA + P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA + P.

Prostate Cancer and Prostatic Diseases (2023) 25:778–784; https://doi.org/10.1038/s41391-022-00533-6
deprivation independent effects. Cessation of LHRH-therapy may lead to rapid recovery of luteinizing hormone (LH) levels, even after long-term medical castration [11, 12]. LH may also act directly on PC cells via LH-specific receptors inducing expression of key steroidogenic enzymes [13] and thus enhancing rescue pathways of testosterone and dihydrotestosterone production [14].

Whether continuation of LHRH therapy in patients with CRPC should be mandatory is debatable and guidelines recommend continuation of LHRH-therapy [15] despite potential side effects and avoidable expenses [16]. Currently, clinical trials are being conducted to investigate the efficacy of AA in different clinical settings (summarized in [16]). The results of the LATITUDE trial [7, 17], showing that the combination of AA + P with ADT in CSPC was associated with significantly longer OS than placebo plus ADT while maintaining a manageable safety profile, further increased the medical need to evaluate the efficacy of AA + P treatment while sparing LHRH-therapy. SPARE was the first study designed to investigate the efficacy of AA + P with and without concomitant LHRH-therapy in patients with mCRPC.

PATIENTS AND METHODS

A detailed description of the SPARE study protocol was previously published [18]. The study protocol was approved by the relevant institutional review boards and independent ethics committees.

Patients

Adult, male patients with histologically or cytologically confirmed adenocarcinoma of the prostate, documented metastatic disease, documented PC progression, asymptomatic or mildly symptomatic from PC, medically castrated (testosterone levels of <0.5 ng/ml), were eligible for inclusion in the study. Exclusion criteria included surgical castration, symptomatic mCRPC (BPI > 3), opioid pain medication, liver or visceral metastasis, and known brain metastasis. Prolonged effects of LHRH-agonists were controlled by in- and exclusion criteria (see Supplementary Table 1).

Trial design and procedures

This was an exploratory Phase 2 multi-center, randomized, open-label study with a randomization allocation ratio of 1:1 [AA + P: LHRH-therapy (Arm A) versus AA + P (Arm B)]. For both groups, patients received a dose of 1000 mg AA and 10 mg P daily. AA was administered as 4 x 250-mg tablets and P was administered as 5 mg orally twice a day (BID). Patients randomized to the LHRH-therapy group received the same LHRH-therapy as prior to enrolment.

The study was conducted between May 2014 and March 2018 at 22 study sites, of which 12 recruited patients, in Germany. Study objectives and endpoints are listed in Table 1. Efficacy assessments included computed tomography and bone-scans every 3 months with disease assessment by the investigator, and PSA levels every 4 weeks. Levels of serum androgens and hormones were analyzed centrally monthly within the first 3 months and every 3 months thereafter. Safety was monitored by documented information on concomitant medication, adverse events (AEs), physical examination, body weight, ECG, cardiac ECHO, and vital signs. Adverse events were coded using the MedDRA coding system and all AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

Table 1. Objectives and endpoints of SPARE study.

| Efficacy endpoint | Description |
|-------------------|-------------|
| Primary efficacy endpoint | Rate of radiographic progression-free survival (rPFS) at month 12 |

Secondary efficacy assessments

- PSA response rate scored in patients achieving a post-treatment PSA decline of at least 50% according to the protocol specific PCWG2 criteria.
- Time to PSA-progression measured from the time interval from the date of randomization to the date of the PSA progression as defined in the protocol-specific PCWG2 criteria. The determination of PSA progression requires that the patient receive at least 3 cycles of therapy.
- Objective response rate in patients with measurable disease (RECIST).
- Value of the bone-scan index as a biomarker of response to treatment.
- Changes in pituitary gonadal axis by measurement of androgens and hormones (LHRH, LH, FSH, testosterone, DHT).

Safety assessments

- Medical history, vital sign measurements, physical examination, and body weight Concomitant therapy and procedures.
- Concomitant therapy and procedures.
- Concomitant therapy and procedures.
- Concomitant therapy and procedures.
- Concomitant therapy and procedures.
- Concomitant therapy and procedures.

Statistical analysis

Patient disposition and efficacy analyses were performed on data from the intention-to-treat (ITT) population (equivalent to Full Analysis Set [FAS]). All patients who received any part of abiraterone acetate were included in the analysis of safety (safety population). Evaluation of an eligible and/or per-protocol population was not specified in the protocol. The baseline measurement was the last value on or before the date of first dose of study drug up through 30 days post last dose.

RESULTS

Patients and treatment

In total, between May 2014 and March 2018, 89 patients were screened at 12 study sites in Germany and 68 patients were
The data are presented as Table 2. Demographic and patient characteristics (ITT population).

| Table 2. Demographic and patient characteristics (ITT population). The data are presented as n (%) unless otherwise noted. |
|---------------------------------------------------------------|
| **Baseline hemoglobin level (g/dl)**                          |
| No metastases                                                 |
| 0–1                                                          |
| 2–3                                                          |
| >3                                                           |
| Analgetic use at baseline                                     |
| No                                                           |
| Yes                                                          |
| Baseline BPI-score                                            |
| 0–1                                                          |
| 2–3                                                          |
| >3                                                           |
| Hormone therapy                                               |
| Leuprorelin                                                   |
| Goserelrin                                                    |
| Buserelin                                                     |
| Pamorelin                                                     |
| Degarelix                                                     |
| Abarelix                                                      |
| Unknown                                                       |
| Time last LHRH to treatment start (days)                      |
| N                                                             |
| Median                                                       |
| Range                                                        |
| Serum testosterone level at baseline (ng/ml)                  |
| N                                                             |
| Median                                                       |
| Range                                                        |
| Metastases at baseline                                        |
| Bone only                                                     |
| Lymph node/soft tissue                                       |
| Bone and Lymph node/soft tissue/prostate                     |
| No metastases                                                 |
| Measurable disease (including primary)                       |
| Yes                                                          |
| No                                                           |
| Baseline PSA (ng/ml)                                          |
| N                                                             |
| Median                                                       |
| Range                                                        |
| Baseline alkaline phosphatase (IU/L)                          |
| N                                                             |
| Median                                                       |
| Range                                                        |
| Baseline LDH (IU/L)                                           |
| N                                                             |
| Median                                                       |
| Range                                                        |
| Previous cancer therapy                                       |
| Prior prostatectomy                                           |
| Prior radiotherapy                                            |
| Hormonal therapy                                              |
| Hormone therapy                                               |
| Leuprorelin                                                   |
| Goserelrin                                                    |
| Buserelin                                                     |
| Pamorelin                                                     |
| Degarelix                                                     |
| Abarelix                                                      |
| Unknown                                                       |
| Age (years)                                                   |
| Median                                                       |
| Range                                                        |
| ECOG                                                         |
| 0                                                            |
| 1                                                            |
| 2                                                            |
| Gleason score at diagnosis                                    |
| 5                                                            |
| 6                                                            |
| 7                                                            |
| 8                                                            |
| 9                                                            |
| 10                                                           |
| Baseline characteristics were balanced between study arms     |

randomly assigned 1:1 (web-based, block of 6) to one of the two study arms (Supplementary Fig. 1); therefore, both arms comprised 34 patients. Of these, 4 (Arm A) and 3 (Arm B) patients did not meet the inclusion criteria and were included by mistake. Two patients in Arm A and one patient allocated to Arm B did not receive study medication. The study was completed according to protocol by 26 patients allocated to Arm A and 21 patients allocated to Arm B. Median treatment duration of the drop-out patients was 93 (Arm A) and 394 (Arm B) days, however, in both arms 6/34 (17.6%) patients dropped out within 12 months of treatment. Treatment compliance, assured by regular drug accountability every 4 weeks during the regular visits of the patients, was good as only 0.1% of AA doses were missed in each Arm. The intention-to-treat population comprised a total of 68 patients (Arm A = 34 patients and Arm B = 34 patients) and the safety population comprised a total of 65 patients (Arm A = 32 patients and Arm B = 33 patients).

Baseline characteristics were balanced between study arms (Table 2). Briefly, median age in Arm A was 74 years (ranging from 60 to 83 years) and in Arm B 76 years (ranging from 60 to 86 years). All patients had previously received hormonal therapy. Median serum testosterone level at baseline was 0.08 ng/ml in Arm A and 0.06 ng/ml in Arm B. Median PSA level at baseline was 31.9 ng/ml in Arm A and 19.5 ng/ml in Arm B. 20 patients (59%) in Arm A and 15 patients (44%) in Arm B had measurable disease (including primary) at baseline.

**Efficacy**

The primary efficacy parameter was the rate of rPFS after 12 months and analysis was based on all patients of the ITT population (FAS analysis). According to the FAS analysis (Table 3 and Fig. 1) the rPFS rate was 0.84 in Arm A (95% CI: 0.6256–0.9366) and 0.89 in Arm B (95% CI: 0.6408–0.9726; log-rank p = 0.5712 at the descriptive level). PSA-response, i.e., the rate of patients achieving a post-treatment PSA decline of at least 50% according to PCWG2 criteria was also calculated. According to FAS analysis, PSA response rate was 64.7% (22/34 patients) in Arm A compared to 73.5% (25/34 patients) in Arm B. Of note, 4 and 2 patients from Arm A and Arm B were not evaluable for PSA-response according to PCWG2. Time to PSA-progression was measured from the time interval from the date of randomization to the date of the PSA progression as defined in the protocol-specific PCWG2 criteria. Determination of PSA
progression required that the patient would have received at least 3 cycles of therapy. According to the ITT population analysis (Table 3 and Fig. 2) the rate of PSA-progression at 12 months was 0.49 in Arm A (95% CI: 0.2534–0.6622) and 0.49 in Arm B (95% CI: 0.2938–0.6589; log-rank \( p = 0.3803 \) at the descriptive level).

Objective response was documented in the eCRF, assessed by investigators according to RECIST criteria and reviewed or corrected where necessary by the principal investigator. At baseline, objective response was documented for 20/32 patients (62.5%) in Arm A and for 15/34 patients (44%) in Arm B. Data regarding objective response at 12 months for all patients with measurable disease at baseline (Arm A: 20/34 patients and Arm B: 15/34 patients) are provided in Table 3. Complete response was documented for 4/20 patients (20%) in Arm A and for 3/15 patients (20%) in Arm B, partial response for 4/20 patients (20%) in Arm A and for 3/15 patients (20%) in Arm B, stable disease for 8/20 patients (40%) in Arm A and for 7/15 patients (46.7%) in Arm B, progressive disease for 2/20 patients (10%) in Arm A and for 0/15 patients (0%) in Arm B, while not evaluable were 2/20 patients (10%) in Arm A and 2/15 patients (13.3%) in Arm B.

Serum testosterone (T) levels, LH and FSH were measured centrally every 4 weeks throughout study treatment. In both arms, median serum testosterone levels decreased after initiation of study treatment to undetectable levels (<0.029 ng/ml) in all patients (Supplementary Fig. 2). In Arm A two patients were included despite non-castrate levels of testosterone (<0.5 ng/ml). LH and testosterone levels of one of the two patients reveals non-compliance with LHRH- and AA treatment causing the peak T level at C19 and the transient rise of mean LH-levels (C13–19), confirmed by drug accountability for AA + P. LH and FSH levels increased only in Arm B within a few cycles of study treatment after stopping LHRH-treatment. Results regarding LH serum levels are provided in Supplementary Fig. 3. Although not pre-specified for analysis in the protocol, T and LH-levels of all eligible patients remains controversial, especially since treatment with AA + P further suppresses testosterone serum levels over LHRH therapy alone. The aim of the SPARE trial was to investigate the added therapeutic value of LHRH-therapy continuation in patients with asymptomatic or mildly symptomatic, chemotherapy naïve mCRPC who commenced treatment AA + P.

Treatment with AA + P alone (i.e., without LHRH-therapy) resulted in high PSA response rates, a long time to PSA progression and rPFS that were comparable to those observed in the randomized, phase 3 clinical trial COU-AA-302 [9]. In addition, AA + P treatment decreased serum testosterone levels in all patients far below 0.5 ng/ml, which is the recommended castrate level [15]. Treatment with AA + P in both arms further suppressed testosterone serum levels compared to the pre-study LHRH-therapy and serum testosterone levels remained stable throughout study treatment.

DISCUSSION

The therapeutic value of LHRH-therapy continuation in mCRPC-patients remains controversial, especially since treatment with AA + P further suppresses testosterone serum levels over LHRH therapy alone. The aim of the SPARE trial was to investigate the added therapeutic value of LHRH-therapy continuation in patients with asymptomatic or mildly symptomatic, chemotherapy naïve mCRPC who commenced treatment AA + P.

Safety evaluation

The safety population comprised all patients receiving any part of study treatment (Arm A = 32 patients and Arm B = 33 patients). Median treatment duration was comparable between the two arms (Arm A = 358 days and Arm B = 394 days).

Adverse events (grade 1–4) occurred in any patient who received any part of study treatment. Moderate and severe adverse events (grade 3–5) were reported for 94% of the patients in Arm A and for 88% of the patients in Arm B. An overview of TEAEs occurring after baseline is provided in Supplementary Table 2. Moderate and severe TEAEs (grade 3–5) were reported for 72% of patients in Arm A and for 85% of patients in Arm B. The most often reported TEAE in both arms was hypertension (Arm A: 69% of patients with grade 1–4 and 33% of patients with grade 3–5; Arm B: 64% of patients with grade 1–4 and 48% of patients with grade 3–5).

Other frequently reported TEAEs in both arms included pain (grade 1–4 only reported; Arm A: 28% and Arm B: 39%) and fatigue (grade 1–4 only reported; Arm A: 22% and Arm B: 21%). The most frequently documented TEAE based on clinical laboratory analysis was hyperglycemia (Arm A: 44% of patients with grade 1–4 and 16% of patients with grade 3–5; Arm B: 61% of patients with grade 1–4 and 18% of patients with grade 3–5).

Serious Adverse Events (SAEs) were reported for 16 patients in Arm A (23 SAEs) and for 15 patients in Arm B (19 SAEs). Relationship to study treatment was assessed by the investigator as possible for 3 SAEs occurring in 3 patients in Arm A (two events of osteonecrosis of the jaw and one event of worsening of general condition) and for 2 SAEs occurring in 2 patients in Arm B (one event of alveolitis and one event of dermatitis). Death was reported for 1 patient in Arm A (1 event of gastric cancer of severe intensity) and for 4 patients in Arm B (1 event of abdominal pain, 1 event of myocardial infarction, 1 event of acute bleeding aortic aneurism, and 1 event of worsening of general condition all of which were of severe intensity). All SAEs leading to death were assessed by the investigator as having no relationship with the study treatment.

| Table 3. Efficacy analysis (ITT population). The data are presented as n (%) unless otherwise noted. |
|---------------------------------------------------------------|

|                        | Arm A (N = 34) | Arm B (N = 34) |
|------------------------|----------------|----------------|
| rPFS at 12 months      |                |                |
| Rate                   | 0.84           | 0.89           |
| 95% CI                 | 0.6256–0.9366  | 0.6408–0.9726  |
| p value (log-rank)     | 0.5712         |                |
| PSA response           |                |                |
| Rate                   | 0.647          | 0.735          |
| PSA-progression at 12 months |          |                |
| Rate                   | 0.49           | 0.49           |
| 95% CI                 | 0.2534–0.6622  | 0.2938–0.6589  |
| p value (log-rank)     | 0.3803         |                |

| Objective response*   |                |                |
|-----------------------|----------------|----------------|
| Complete response     | 4 (20%)        | 3 (20%)        |
| Partial response      | 4 (20%)        | 3 (20%)        |
| Stable disease        | 8 (40%)        | 7 (46.7%)      |
| Progressive disease   | 2 (10%)        | 0 (0%)         |
| Not evaluable         | 2 (10%)        | 2 (13.3%)      |

*Based on the number of randomized patients with measurable disease at baseline (Arm A: 20 patients and Arm B: 15 patients).

Although SPARE was an exploratory study and thus no clear statistical inferences can be made, the results obtained suggest that discontinuation of LHRH-therapy may not result to decreased clinical activity (by means of rPFS assessment) and therefore challenge the practice of using continuous LHRH-therapy in mCRPC patients. Of note, the drop-out rate within the first 12 months of treatment was the same (17.6%) in both Arms so that it is unlikely that the rate of rPFS at month 12 was influenced by the dropouts. However, secondary endpoints like time to PSA progression may have been influenced by the unequal distribution and treatment duration of the drop-out patients between treatment arms.
Recently, the results from the phase 2 LACOG 0415 trial in patients with hormone-sensitive advanced/metastatic prostate cancer evaluating the use of AA + P + ADT versus apalutamide (APA) alone versus AA + P + APA were published [19]. In this trial all patients had non-castrate testosterone levels and at week 25 of treatment, the rate of patients with PSA-levels of ≤0.2 ng/ml and of radiographic progression were similar in patients receiving AA + P + APA or AA + P + ADT. In addition, testosterone serum levels decreased significantly upon treatment with AA + P + APA. However, median testosterone levels were higher in patients receiving AA + P + APA. Some patients did not reach castrate levels of testosterone (≤0.5 ng/ml) and the mean change of testosterone levels from baseline to week 25 was lower in the AA + P + APA arm compared to AA + P + ADT. The reduced efficacy of testosterone suppression may be caused, at least in part, by a compensatory increase in serum LH levels, as previously reported [20].

In contrast to the results in LACOG 0415 trial, testosterone serum levels remained undetectable in the SPARE-trial. This is in line with previous reports on maximum testosterone decline by AA + P [21]. Long-term LHRH-therapy with prolonged impairment of testicular testosterone synthesis may have affected the measured testosterone serum levels. However, the detected testosterone serum levels in all patients were far below levels
that can be achieved by LHRH-therapy alone. Therefore, we conclude that suppression of testosterone serum levels in Arm B of the study was caused by the effects of abiraterone only.

A similar compensatory increase of LH and FSH levels as mentioned above within a few months after discontinuation of LHRH therapy was detected in Arm B of the SPARE trial, reflecting the clinical scenario of hypergonadotropic hypogonadism. The elevated LH and FSH levels warrant no further interventions since the suppressed testosterone level is the driver of the clinical effects. However, a rapid increase of testosterone serum levels was detected in some patients after discontinuation of AA treatment within 4 weeks, reverting the clinical scenario into hypergonadotropic hypogonadism. If the replenished testosterone serum levels are harmful to the prostate cancer patients remains controversial. Further clinical trials are needed to determine the optimal management of patients receiving long-term medical castration therapy for prostate cancer.

In Arm B of the SPARE trial, the effects of abiraterone alone were also investigated in clinical trials with the ability to re-sensitize patients to LHRH-therapy upon treatment with AA in mCRPC patients. However, further trial confirmatory analyses are required to demonstrate the efficacy of AA treatment without continuous LHRH-therapy in mCRPC patients.

**DATA AVAILABILITY**

All data are available upon request. The protocol can be accessed at www.clinicaltrials.gov.

**REFERENCES**

1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:63–89.
2. Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. OncoTargets Ther. 2016;9:263–74.
3. Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol. 2008;53:1129–37.
4. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkert E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–8.
5. de Bono JS, Logothetis CJ, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
6. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Updated efficacy data for abiraterone acetate plus prednisone in patients with mCRPC. J Clin Oncol. 2017;35:2154–61.
7. Fizazi K, Tran N, Fein L, Matsubara N, Rodríguez-Antolín A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.
8. Ohlmann C-H, Jäschke M, Jaehnig S, Schmid M, Kuczyński R, Reher H, et al. Androgen-deprivation therapy with abiraterone acetate and prednisone in patients with progressive, metastatic, and chemotherapy-naive, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials. 2017;18:457.
9. Mehta J, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Cancer Res. 2011;71:5844–9.
Manuscript editing and review. EH: Patient data and study materials, Manuscript editing and review. HS: Patient data and study materials, Manuscript editing and review. MJ: Patient data and study materials, Manuscript editing and review. JM: Patient data and study materials, Manuscript editing and review. AH: Patient data and study materials, Manuscript editing and review. MM: Patient data and study materials, Manuscript editing and review. JG: Patient data and study materials, Manuscript editing and review. MS: Patient data and study materials, Manuscript editing and review. SF: Patient data and study materials, Manuscript editing and review. JT: Patient data and study materials, Manuscript editing and review. JK: Patient data and study materials, Manuscript editing and review. MS: Patient data and study materials, Manuscript editing and review.

FUNDING
The trial was financially supported by Janssen-Cilag GmbH, Germany. Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS
The authors declare no conflicts of interests other than the financial support of the trial by Janssen-Cilag GmbH, Germany.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study was conducted in accordance with the Declaration of Helsinki approved by the trial-leading Ethics Committee of the Saarland (reference number 143/13) and the Ethics Committees of each trial site. All patients gave written informed consent prior to participation in the trial.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41391-022-00533-6.

Correspondence and requests for materials should be addressed to Carsten-Henning Ohlmann.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.